Related Experiment Video

Updated: Oct 31, 2025

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.3K

[Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in 
Non-small Cell Lung Cancer]

Peng Wang1, Chuanhao Tang2, Jun Liang1

  • 1Department of Radiation Oncology, Peking University International Hospital, Beijing 102206, China.

Zhongguo Fei AI Za Zhi = Chinese Journal of Lung Cancer
|June 30, 2021
PubMed

Insights

Blood biomarkers offer a non-invasive alternative to tissue tests for advanced non-small cell lung cancer (NSCLC) patients receiving immune checkpoint inhibitors (ICI). These biomarkers show promise in predicting outcomes and monitoring treatment response, aiding precision immunotherapy.

Area of Science:

  • Oncology
  • Immunology
  • Translational Medicine

Background:

  • Immune checkpoint inhibitors (ICI) have revolutionized advanced non-small cell lung cancer (NSCLC) treatment.
  • Tissue-based biomarkers like PD-L1 expression and tumor mutational burden (TMB) are standard but have limitations.
  • Tissue accessibility and heterogeneity pose challenges for accurate patient selection and monitoring.

Purpose of the Study:

  • To review current knowledge on blood-based biomarkers for NSCLC patients undergoing ICI therapy.
  • To highlight the potential of liquid biomarkers in guiding precision immunotherapy.
  • To provide references for the development of novel blood biomarkers.

Main Methods:

  • Literature review of studies on blood biomarkers in NSCLC and ICI treatment.
  • Analysis of current clinical applications and limitations of tissue-based biomarkers.
  • Exploration of the utility of blood biomarkers for outcome prediction and response monitoring.

Main Results:

  • Blood biomarkers offer a non-invasive approach to assess immune status and tumor characteristics.
  • Liquid biomarkers can potentially overcome the limitations of tissue heterogeneity.
  • Emerging evidence supports their role in predicting treatment response and monitoring efficacy.

Conclusions:

  • Blood biomarkers represent a promising alternative to tissue-based markers in NSCLC immunotherapy.
  • Further research is needed to validate and implement these biomarkers in clinical practice.
  • Development of novel blood biomarkers can enhance precision medicine strategies for NSCLC.
Keywords:
Blood biomarkersImmmune Checkpoint InhibitorsImmunotherapyLung neoplasms

More Related Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.8K
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
785